Get the Stockscreener App
6.25
1.63%
0.10
Pre-market:
6.25
Cvrx Inc stock is traded at $6.25, with a volume of 241.65K.
It is up +1.63% in the last 24 hours and down -46.81% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$6.15
Open:
$6.12
24h Volume:
241.65K
Relative Volume:
0.82
Market Cap:
$170.02M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-2.3106
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
-3.55%
1M Performance:
-46.81%
6M Performance:
-22.84%
1Y Performance:
-60.22%
1-Day Range:
$6.02
$6.28
1-Week Range:
$5.91
$6.7076
52-Week Range:
$5.865
$18.55
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
6.25 | 170.02M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx, Inc. (NASDAQ:CVRX) Shares Acquired by JPMorgan Chase & Co. - Defense World
CVRx, Inc. (NASDAQ:CVRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
(CVRX) Investment Analysis - news.stocktradersdaily.com
Cantor maintains CVRx stock with $20 target despite revenue miss By Investing.com - Investing.com India
Cantor maintains CVRx stock with $20 target despite revenue miss - Investing.com
William Blair Comments on CVRx’s Q1 Earnings (NASDAQ:CVRX) - Defense World
CVRx's SWOT analysis: barostim maker's stock faces growth hurdles By Investing.com - Investing.com India
CVRx stock slides on preliminary revenue miss - MSN
CVRx, Inc.: Overreaction Creates Buying Opportunity - Seeking Alpha
CVRx Insiders Lose Out As Stock Sinks To US$6.20 - simplywall.st
CVRx’s SWOT analysis: barostim maker’s stock faces growth hurdles By Investing.com - Investing.com India
CVRx's SWOT analysis: barostim maker's stock faces growth hurdles - Investing.com
Cantor Fitzgerald maintains CVRx stock Overweight rating By Investing.com - Investing.com South Africa
CVRx stock touches 52-week low at $6.36 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
CVRx stock drops on Q1 preliminary sales number miss - MassDevice
CVRx stock touches 52-week low at $6.36 amid market challenges - Investing.com
Cantor Fitzgerald maintains CVRx stock Overweight rating - Investing.com
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Benzinga
CVRx price target lowered to $14 from $19 at Lake Street - TipRanks
Assessing CVRx: Insights From 4 Financial Analysts - Benzinga
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Canaccord cuts CVRx stock target to $18, maintains Buy rating By Investing.com - Investing.com India
Top Premarket Decliners - MarketScreener
Canaccord cuts CVRx stock target to $18, maintains Buy rating - Investing.com
CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
CVRx (CVRX) Stock Drops as Preliminary Q1 2025 Revenue Disappoin - GuruFocus
CVRx stock slides on preliminary revenue miss (CVRX:NASDAQ) - Seeking Alpha
CVRx Sees Q1 Higher Revenue YOY, Missing Consensus -- Shares Fall After Hours - MarketScreener
CVRx Reports Preliminary First Quarter 2025 Financial Results - The Manila Times
CVRx Posts Mixed Q1 Earnings: 15% Growth Meets Headwinds as Expansion Continues - Stock Titan
(CVRX) Long Term Investment Analysis - news.stocktradersdaily.com
Bank of New York Mellon Corp Increases Stake in CVRx, Inc. (NASDAQ:CVRX) - Defense World
CVRx stock plunges 42% in wake of Q1 report, updated forecast - MSN
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Several Insiders Invested In CVRx Flagging Positive News - Yahoo
Cantor Fitzgerald maintains CVRx stock with $20 target By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains CVRx stock with $20 target - Investing.com
(CVRX) Trading Report - Stock Traders Daily
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For - Simply Wall St
Power Shift 25: Medtech firm's new CEO looks to 'build a world-class team'Minneapolis / St. Paul Business Journal - Minneapolis / St. Paul Business Journal
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analyzing Co-Diagnostics (NASDAQ:CODX) and CVRx (NASDAQ:CVRX) - Defense World
CVRx, Inc. (NASDAQ:CVRX) Short Interest Down 9.8% in January - Defense World
CVRx, Inc. SEC 10-K Report - TradingView
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com UK
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim - GlobeNewswire
Cvrx, Inc. Announces New Real-World Evidence Demonstrating Significant Reductions in Healthcare Utility with Barostim - Marketscreener.com
CVRx, Inc. Presents New Real-World Evidence Demonstrating Significant Reductions in Hospital Visits After Barostim Implantation at THT Conference 2025 - Nasdaq
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):